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We aimed to explore novel small metabolites that associated with hypertension risk in a population-based nested case-control
study. Among 460 individuals with optimal blood pressure (<120/80mmHg) at baseline, 55 progressed to hypertension during 5
years of follow-up. Twenty-nine cases of incident hypertension and 29 controls, matched for age, sex, and baseline systolic blood
pressure, were included in this study. Serummetabolites were measured by gas chromatography-tandemmass spectrometry. 𝑡-test
and logistic regression analysis were applied to investigate the association between metabolites and incident hypertension. Among
the 241 metabolites identified in this study, baseline levels of 26 metabolites were significantly different between hypertension and
control groups. After adjusting for body mass index, smoking, and drinking, 16 out of the 26 metabolites were still associated with
hypertension risk including four amino acids. Amino acids were negatively associated with risk of future hypertension, with odds
ratio (OR) ranging from 0.33 to 0.53. Two of these amino acids were essential amino acids including threonine and phenylalanine.
Higher level of lyxose, a fermentation product of gutmicrobes, was associatedwith higher risk of hypertension. Our study identified
multiple metabolites that associated with hypertension risk.These findings implied that low amino acid levels and gut microbiome
might play an important role in the pathogenesis of hypertension.
1. Introduction
Hypertension is a key risk factor for cardiovascular diseases.
It is estimated that 2.33 million cardiovascular deaths were
attributable to increased blood pressure (BP) in China [1].
With the economic development and lifestyle changes in
recent years, there has been a dramatic increase in the
prevalence of hypertension in China [2]. Prevention of
hypertension can help to reduce the public health burden
of cardiovascular diseases [3]. It is critical to understand the
mechanisms underlying elevated BP and develop reliable pre-
vention strategies for populations at high risk of developing
hypertension.
Hypertension is a metabolic disease and its pathophysi-
ology is still unclear. Recent advances in metabolomic tech-
nologies have enhanced the feasibility of acquiring high-
throughput profiles of a whole organism’s metabolic status
[4]. As these techniques allow assessment of large numbers
of small metabolites that are substrates and products in
metabolic pathways, metabolomics can particularly increase
the understanding of the pathophysiology of metabolic dis-
eases such as hypertension [5]. Although some studies have
evaluated metabolomic differences in participants with and
without hypertension [6–11], few have sought to identify
baseline metabolites that predict future hypertension [12].
Metabolites identified in these studies that associated with
hypertension were not well replicated. There are great meta-
bolic differences between populations [8] and no study has
explored the relationship between metabolites and risk of
hypertension in Chinese population, which has the largest
number of hypertensive patients [13]. Therefore, we aimed to
explore small metabolites that independently associated with
incident hypertension in a cohort based nested case-control
study. In addition, we used pathway analysis to identify
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2. Materials and Methods
2.1. Study Participants. Participants were recruited from the
Chinese Multiprovincial Cohort Study- (CMCS-) Beijing
Project [14], part of the nationwide population-based CMCS
study investigating the risk factors related to the incidence
of cardiovascular diseases [15]. The flow chart of participant
selection was presented in Fig. S1 in Supplementary Material
available online at http://dx.doi.org/10.1155/2016/7646979. Of
the 1478 participants who were free of hypertension and
completed the baseline examination in 2002, 1133 took
part in follow-up examination in 2007, with a follow-up
rate of 76.7%. Among them, 460 were with optimal BP
(<120/80mmHg) at baseline. Fifty-five of these 460 partic-
ipants developed hypertension and 208 participants were
still with optimal BP in 2007. In this nested case-control
study, 34 cases were randomly selected from the 55 partici-
pants who had optimal BP in 2002 and developed incident
hypertension during follow-up. For each hypertensive case,
we selected a control with optimal BP in both 2002 and
2007 and matched for gender, age (±3 years), and baseline
systolic BP (±5mmHg). Hypertension was defined as BP ≥
140/90mmHg and/or on antihypertensive therapy [16]. After
excluding participants with more than 80% of metabolites
below the detection limit or missing (five cases and five
controls), 58 participants (29 cases and 29 controls) were
eligible for final analysis. There was no significant difference
in baseline characteristics between included participants and
those excluded (Table S1).
All participants signed informed consent, and the Ethics
Committee of Beijing An Zhen Hospital, Capital Medical
University, reviewed and approved the protocols of this study.
2.2. Risk Factor Survey. The surveys in 2002 and 2007 were
both conducted based on the WHO-MONICA (Monitoring
of Trends and Determinants in Cardiovascular Disease)
protocol for risk factor surveys. A standard questionnaire was
designed to collect information on demographic character-
istics, status of smoking and alcohol drinking, and personal
medical history. Current smoking was defined as having
smoked at least one cigarette per day in the past year. Drink-
ing was defined as drinking at least once a week. Anthropo-
metric measurements were recorded during physical exam-
ination. Body mass index (BMI) was calculated as weight
in kilograms divided by height squared in meters. BP was
measured in the right arm at a sitting position with a regular
mercury sphygmomanometer after resting for at least 5min.
The mean value of two consecutive BP readings was used.
2.3. LaboratoryAssays. Fasting total cholesterol (TC), triglyc-
eride (TG), and fasting blood glucose (FBG)were determined
by enzymatic methods. Low-density lipoprotein cholesterol
(LDL-C) and high-density lipoprotein cholesterol (HDL-
C) were measured by homogeneous assay (Daiichi, Tokyo,
Japan). Overnight fasting venous blood samples were col-
lected for laboratory measurements. To avoid the introduc-
tion of any analytical bias due to sample preparation, all
samples were kept at room temperature to clot for 30minutes
and then put in ice box. Blood samples were centrifugated
for 10min (4000×g, 25∘C) within three hours after blood
collection. Serum was frozen at −80∘C until execution of
metabolomic analyses.
Metabolite profiles were measured using the gas chroma-
tography-tandem mass spectrometry (GC/MS) method.
Serum samples were thawed at room temperature for 15min
and vortex-mixed for 5 s. For GC/MS measurement, 300 𝜇L
pure ethanol (HPLC grade: Sigma-Aldrich, St. Louis, MO,
USA) was added to a 100 𝜇L serum sample in an Eppendorf
tube. The mixture was vortex-mixed for 30 s and allowed to
stand for 20min at 4∘C. After 80 𝜇L pure methanol (HPLC
grade: Sigma-Aldrich) was added, the mixture was vortex-
mixed for another 30 s and centrifuged at 4∘C at 12000 rpm
for 15min. Then, 150𝜇L of the supernatant was transferred
to a screw vial and 10 𝜇L dichlorophen (0.02mg/mL: Sigma-
Aldrich) was added as the internal standard. The mixture
was evaporated to dry under a stream of nitrogen gas
(4∘C). After 30 𝜇L methoxyamine pyridine hydrochloride
(20mg/mL) was added into the screw vial, the mixture was
vortex-mixed for 30 s and oximated at 37∘C for 90min. We
added 30 𝜇L N,O-bis(trimethylsilyl)trifluoroacetamide with
1% trimethylchlorosilane (Sigma-Aldrich) to each vial and
left the mixture to react at 70∘C for 60min. The samples
were allowed to stand for 15min at room temperature before
GC/MS analysis.
A 1 𝜇L aliquot of derivatized sample was injected in
splitless mode into an Agilent 7890A GC system equipped
with a 30m × 0.25mm × 0.25 𝜇m capillary column (Agilent
J&W Scientific, Folsom, CA, USA).The injector temperature
was set at 280∘C and helium was used as carrier gas. The
column temperature was initially kept at 80∘C for 2min, then
increased from 80∘C to 320∘C at 10∘C min−1, and held for
6min.The column effluent was introduced into ion source of
an Agilent 5975C mass detector. The ion source temperature
was set at 230∘C and the MS quadrupole temperature at
150∘C [17]. Masses were acquired from 50 to 550 m/z. For
quality control, we performed metabolite profiling in the
same quality control serum sample, enabling detection of
temporal drift in instrument performance. Each of these
injections into the mass spectrometer was generated from
a distinct 10 𝜇L aliquot of pooled serum, extracted, and
processed individually. The coefficients of variations (CVs)
for each metabolite across a total of six replicates of quality
control serum sampleswere calculated. Seventy-eight percent
of the metabolites had CVs of less than or equal to 20%.
GC/MSD ChemStation Software (Agilent, Shanghai,
China) was used for autoacquisition of GC total ion chro-
matograms and fragmentation patterns. Each compound
had a fragmentation pattern comprising a series of split
molecular ions; the mass charge ratios and their abundance
were compared with a standard mass chromatogram in the
National Institute of Standards and Technology (NIST) mass
spectra library by the ChemStation Software. For each peak,
the software generated a list of similarities comparing with
every substancewithin theNIST library. Peakswith similarity
index more than 70% were assigned compound names.
2.4. Statistical Analyses. Natural logarithm transformation
was performed for continuous variables to minimize the
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skewedness of distribution if necessary. Metabolites with
<50% BDL/missing observations were treated as continuous
variables in the analyses; and metabolites with 50%–80%
BDL/missing observations were treated as ordinal variables.
A two-sample 𝑡-test or Wilcoxon rank-sum test was used
for comparison of metabolite levels between hypertension
and control groups. We also performed logistic regression
analysis to investigate the association between metabolites
and incident hypertension, adjusting for BMI, smoking, and
drinking. A sample size of 58 (29 in hypertension group
and 29 in control group) has a power of 0.88 to detect
the difference between two groups, assuming the mean
concentrations of 11.6 ± 2.57 and 9.65 ± 2.15 𝜇mol/L in
hypertension and control groups, respectively [18], with a
significance level of 0.05. A Bonferroni procedure was used
to correct formultiple comparisons and a significance level of
2.07 × 10−4 (2-tailed) was considered for each individual test.
Statistical analysis was performed with SAS 9.2 (SAS Institute
Inc., Cary, NC, USA).
Metabolite set enrichment analysis was performed by
MetaboAnalyst 2.0, a comprehensive, web-based tool desig-
ned for processing, analyzing, and interpreting metabolomic
data [19]. Overrepresentation analysis was implemented
using the hypergeometric test to evaluatewhether a particular
metabolite set was represented more than that expected by
chance within a given compound list [19]. Metabolites with
significant 𝑃 values for hypertension risk were given as input
in our study.
3. Results
3.1. Baseline Characteristics. Of the 1133 participants who
were free of hypertension and were followed up for 5 years,
460 were with optimal BP at baseline. Among them, 55 devel-
oped hypertension during follow-up. Baseline characteristics
of 29 new hypertensive cases and 29 controls included in
this study are shown in Table 1. Age, gender, and systolic BP
were matched variables.There were no significant differences
in BMI, diastolic BP, FBG, TC, LDL-C, HDL-C, CRP, and
creatinine at baseline between cases and controls.
3.2. Baseline Metabolite Levels and Risk of Hypertension. A
total of 241 metabolites were identified in this study and the
associations between baseline metabolite levels and risk of
new onset hypertension were evaluated. Baseline levels of 26
metabolites were different between hypertension and control
groups, including eight amino acids, seven carbohydrates,
four carboxylic acids, three phenols, and four metabolites of
other classes (Table 2). Five of these metabolites remained
significant after Bonferroni correction including threonine
(𝑃 = 1.78×10−4), talose (𝑃 = 9.01×10−5), lyxose (𝑃 = 4.26×
10
−5), methylmalonic acid (𝑃 = 2.37 × 10−5), and malonic
acid (𝑃 = 1.24 × 10−5), and one with marginal significance
(galactose, 𝑃 = 5.71 × 10−4). Hypertension cases had lower
baseline levels of amino acids than controls. After adjusting
for BMI, smoking, and drinking, 16 out of the 26 metabolites
were still significantly associated with hypertension risk and
two of them were essential amino acids including threonine
(odd ratio (OR): 0.33, 95%CI: 0.16–0.70,𝑃 = 1.78×10−4) and
phenylalanine (OR: 0.49, 95% CI: 0.26–0.91, 𝑃 = 1.12×10−2).
A higher baseline level of lyxose, a fermentation product of
gutmicrobes, was associated with higher risk of hypertension
(OR: 2.88, 95% CI: 1.44–5.73, 𝑃 = 4.26 × 10−5) (Table 2).
3.3. Relationship between Baseline Levels of Metabolites. We
assessed correlations between baseline levels of 26 metabo-
lites associated with hypertension risk. Amino acids were
positively correlated with phenols and negatively correlated
with carbohydrates and carboxylic acids (Figure 1). Pheny-
lalanine was positively correlated with downstream metabo-
lites within the phenylalanine and tyrosine metabolism path-
way including tyrosine (𝑟 = 0.73) and norepinephrine (𝑟 =
0.39). Talose level was positively correlated with methyl-
malonic acid (𝑟 = 0.57) and malonic acid (𝑟 = 0.64) and
negatively correlated with threonine (𝑟 = −0.52).
Pathway enrichment analysis was performed using the
26 metabolites associated with hypertension risk to identify
novel pathways implicated in hypertension. Three metabolic
pathwayswere identified, includingmetabolismof phenylala-
nine, tyrosine, and tryptophan biosynthesis (𝑃 = 1.92×10−3),
aminoacyl-tRNAbiosynthesis (𝑃 = 4.91×10−3), and nitrogen
metabolism (𝑃 = 5.57 × 10−3) (Table 3). Of note, four out of
fivemetabolites involved in these pathways were amino acids.
4. Discussion
Our study aimed to investigate human serum metabolites
and hypertension risk in a well-defined nested case-control
setting in a Chinese population. This nested case-control
study examined metabolite profiles associated with the risk
of hypertension. We identified a panel of metabolites whose
baseline levels were associated with future development of
hypertension. We found that participants who developed
hypertension had reduced serum levels of amino acids,
which implied that amino acids play an important role in
development of hypertension. In addition, a gut microbial
metabolite, lyxose, was associated with an elevated risk of
hypertension.
It is worth noting that low levels of amino acids were
associated with higher risk of hypertension in our study
and two of them are essential amino acids (threonine and
phenylalanine). Essential amino acids cannot be synthesized
by the body, and levels of these amino acids in the body
may mainly be decided by dietary protein intake. Recent
studies suggest that inadequate intake of proteinmay lead to a
shortage of essential amino acids and a subsequent elevation
in BP [20, 21]. Evidence from randomized clinical trials
indicates that administration of amino acids can improve
endothelial function and decrease peripheral vascular resis-
tance, resulting in decreased BP [22]. Amino acidmetabolism
may also regulate BP through insulin signaling, as it is
essential to normal pancreatic 𝛽-cell function and insulin
secretion [23]. In recent decades, the dietary pattern has
changed rapidly in China. Data from the China Health and
Nutrition Survey showed that the percentage of energy con-
sumed from fat and protein (especially animal protein) had
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Table 1: Baseline characteristic of study participants.
Characteristics Individuals who developedhypertension (𝑛 = 29)
Individuals with optimal
blood pressure (𝑛 = 29) 𝑃
∗
Age (years) 52.1 ± 4.2 51.9 ± 4.1 0.84
Men (%) 44.8 41.4 0.79
BMI (kg/m2) 23.2 ± 2.6 24.0 ± 2.8 0.31
SBP (mmHg) 110.8 ± 6.6 110.2 ± 6.4 0.72
DBP (mmHg) 72.9 ± 4.1 72.4 ± 4.8 0.79
FBG (mg/dL) 83.9 ± 12.7 82.4 ± 7.9 0.60
TG (mg/dL) 84 (65, 106) 96 (64, 111) 0.64
TC (mg/dL) 202.9 ± 35.1 199.9 ± 30.0 0.73
LDL-C (mg/dL) 121.1 ± 30.3 116.5 ± 23.1 0.52
HDL-C (mg/dL) 56.6 ± 10.7 60.7 ± 15.9 0.26
CRP (mg/dL) 0.60 (0.30, 0.81) 0.68 (0.25, 1.17) 0.30
Creatinine (mg/dL) 0.99 ± 0.17 0.96 ± 0.18 0.54
Smoking (%) 20.7 10.3 0.47
Drinking (%) 13.8 6.9 0.67
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; FBG: fasting blood glucose; TG: triglycerides; TC: total cholesterol; LDL-
C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; CRP: C reactive protein. Data are expressed as a percent for categorical
variables, as mean ± standard deviation for continuous variables in cases of normally distributed data, and as medians (interquartile ranges) otherwise. ∗𝑃
values for the difference between two groups.
Table 2: Association of metabolites with incident hypertension.
Class Metabolite RT Fold change 𝑃 OR 𝑃adj
Amino acids and derivatives
Threonine 21.87 0.12 1.46 × 10−4 0.33 (0.16–0.70) 1.78 × 10−4
Nicotinoyl glycine 8.28 0.49 2.31 × 10−2 0.52 (0.28–0.96) 1.21 × 10−2
Glycine 8.58 0.36 2.71 × 10−2 0.78 (0.44–1.38) 1.31 × 10−1
Phenylalanine 13.02 0.70 3.44 × 10−2 0.49 (0.26–0.91) 1.12 × 10−2
S-Carboxymethylcysteine 24.78 0.49 4.03 × 10−2 0.58 (0.32–1.05) 6.56 × 10−2
Tyrosine 16.70 0.58 4.76 × 10−2 0.73 (0.42–1.29) 3.79 × 10−1
Aspartic acid 21.22 0.55 4.92 × 10−2 0.53 (0.28–0.99) 2.38 × 10−2
Gly-Pro 13.38 0.40 4.99 × 10−2 0.71 (0.4–1.23) 1.02 × 10−2
Carbohydrate
Talose 16.88 10.88 1.69 × 10−6 11.64 (3.39–39.96) 9.01 × 10−5
Lyxose 14.47 2.29 1.24 × 10−4 2.88 (1.44–5.73) 4.26 × 10−5
Galactose 16.49 0.22 2.81 × 10−4 0.34 (0.17–0.7) 5.71 × 10−4
Glucose-1-phosphate 16.41 1.04 × 10−6 1.06 × 10−3 0.34 (0.16–0.71) 2.40 × 10−3
Methyl-beta-D-galactopyranoside 14.32 0.37 6.73 × 10−3 0.28 (0.13–0.6) 1.20 × 10−3
Dihydroxyacetone 7.06 0.50 3.12 × 10−2 0.62 (0.34–1.11) 9.84 × 10−2
Melezitose 23.25 0.48 3.81 × 10−2 0.54 (0.29–1.01) 8.38 × 10−2
Carboxylic acids and derivatives
Methylmalonic acid 8.13 3.04 1.47 × 10−7 5.24 (2.1–13.03) 2.37 × 10−5
Malonic acid 11.16 12.47 3.29 × 10−5 12.55 (3.4–46.39) 1.24 × 10−4
Shikimic acid 14.33 5.56 5.85 × 10−3 5.06 (2.07–12.33) 3.00 × 10−4
Oxalic acid 6.19 0.56 3.29 × 10−2 0.57 (0.31–1.02) 7.11 × 10−2
Phenols and derivatives
Thymol 14.17 0.31 4.14 × 10−3 0.43 (0.23–0.83) 6.00 × 10−3
Noradrenaline 8.45 0.49 7.05 × 10−3 0.46 (0.24–0.87) 5.49 × 10−3
2-Aminophenol 9.19 0.34 1.02 × 10−2 0.55 (0.29–1.01) 5.44 × 10−2
Others
2-Methoxyestrone 19.65 0.57 1.74 × 10−2 0.39 (0.2–0.76) 8.71 × 10−3
Alpha-tocopherol 27.36 0.60 3.23 × 10−2 0.47 (0.25–0.89) 3.82 × 10−2
Octadecanol 19.08 0.56 3.98 × 10−2 0.64 (0.36–1.14) 2.47 × 10−1
2-Aminoethanethiol 6.08 0.59 4.26 × 10−2 0.59 (0.32–1.06) 9.38 × 10−2
RT: retention time; fold change: ratio of metabolite levels between case and control groups; OR: odds ratio; 𝑃adj: 𝑃 value adjusted for BMI, smoking, drinking,
creatinine and C reactive protein, and postmenopausal status.
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Table 3: Pathways associated with risk of hypertension.
Pathway Total Expected Hit Metabolites 𝑃∗
Phenylalanine, tyrosine, and tryptophan
biosynthesis 27 0.26 3 Phenylalanine, tyrosine, shikimic acid 1.92 × 10
−3
Aminoacyl-tRNA biosynthesis 75 0.72 4 Phenylalanine, glycine, threonine,tyrosine 4.91 × 10
−3
Nitrogen metabolism 39 0.37 3 Phenylalanine, tyrosine, glycine 5.57 × 10−3
Total: the total number of compounds in the pathway. Expected: the expected matched number from the 26 metabolites associated with hypertension. Hit: the
actual matched number from the 26 metabolites associated with hypertension. ∗𝑃: 𝑃 value calculated from enrichment analysis.
1.00
and derivatives 0.73 1.00
Absolute value of correlation 0.7–1
0.36 0.52 1.00
Absolute value of correlation 0.3–0.7
0.19 0.30 0.15 1.00
Absolute value of correlation 0–0.3
0.66 0.60 0.47 0.30 1.00
0.07 Negative correlation
0.36 0.43 0.35 0.73 0.44 1.00
0.07 Positive correlation
0.55 0.60 0.27 0.44 0.61 0.49 1.00
0.45 0.49 0.51 0.30 0.49 0.64 0.35 1.00
0.46 0.47 0.12 0.39 0.41 0.44 0.55 0.26 1.00and derivatives
0.56 0.50 0.09 0.27 0.19 0.18 0.40 0.01 0.56 1.00
0.62 0.45 0.11 0.27 0.38 0.22 0.43 0.12 0.57 0.71 1.00
0.81 0.83 0.41 0.27 0.64 0.32 0.61 0.29 0.37 0.53 0.49 1.00Carbohydrate 0.52 0.26 0.02 0.15 0.23 0.14 0.26 0.17 0.57 0.64 0.76 0.22 1.00
0.20 0.22 0.04 0.13 0.18 0.20 0.30 0.04 0.64 0.41 0.33 0.16 0.39 1.00
0.04 0.15 0.11 0.10 0.16 0.04 0.02 0.16 0.30 0.01 0.20 0.24 0.31 0.28 1.00
0.04 0.06 0.27 0.20 0.14 0.10 0.16 0.09 0.22 0.01 0.07 0.09 0.24 0.19 0.31 1.00
0.10 0.05 0.02 0.23 0.20 0.17 0.01 0.31 0.11 0.17 0.22 0.07 0.44 0.06 0.49 0.28 1.00
0.55 0.66 0.61 0.20 0.46 0.29 0.44 0.46 0.28 0.19 0.25 0.54 0.18 0.06 0.08 0.07 0.10 1.00
0.23 0.24 0.10 0.03 0.36 0.10 0.24 0.01 0.29 0.20 0.22 0.36 0.17 0.23 0.18 0.13 0.01 0.28 1.00
0.51 0.56 0.27 0.09 0.40 0.30 0.25 0.47 0.41 0.42 0.32 0.50 0.23 0.18 0.15 0.28 0.15 0.18 0.29 1.00
derivatives 0.70 0.84 0.41 0.39 0.56 0.40 0.59 0.40 0.43 0.54 0.43 0.87 0.30 0.22 0.16 0.02 0.08 0.55 0.27 0.45 1.00
0.43 0.42 0.35 0.01 0.32 0.06 0.24 0.22 0.09 0.12 0.23 0.40 0.20 0.16 0.09 0.09 0.11 0.40 0.26 0.20 0.41 1.00
Others 0.50 0.49 0.24 0.51 0.61 0.45 0.76 0.27 0.52 0.43 0.47 0.58 0.32 0.23 0.04 0.12 0.02 0.24 0.33 0.35 0.57 0.22 1.00
0.59 0.55 0.37 0.42 0.51 0.36 0.70 0.19 0.46 0.46 0.47 0.64 0.31 0.16 0.01 0.01 0.10 0.54 0.13 0.19 0.60 0.22 0.60 1.00
0.30 0.23 0.28 0.34 0.38 0.35 0.30 0.47 0.17 0.11 0.11 0.26 0.26 0.06 0.13 0.09 0.45 0.29 0.20 0.22 0.33 0.04 0.37 0.42 1.00





























































































































































































































Figure 1: Correlation matrix for serum metabolite levels. This figure shows Spearman correlation coefficients for baseline levels of 26
metabolites that were different between hypertension and control groups. Correlation coefficients in red represent a negative correlation
and in black represent a positive correlation.
been increased in the past decades, while energy consumed
from carbohydrate had decreased in China [24, 25]. However,
protein intakes of majority of population were still below the
amount recommended by dietary guidelines.
The effects of threonine and phenylalanine on hyperten-
sion are supported by findings from experimental studies.
In Sprague-Dawley rats, threonine-deficient diets can induce
a specific uncoupling of mitochondria [26] and reduce
mitochondrialATPproduction.Attenuated intracellularATP
content results in elevated BP by increased sympathetic ner-
vous system activation, whereas augmented reactive oxygen
production following mitochondrial dysfunction lowers the
capacity of nitric oxide-dependent vascular relaxation [27,
28]. Phenylalanine intervention could exert an antihyperten-
sion effect on spontaneously hypertensive rats (SHR) [29].
The antihypertensive action of phenylalanine observed in
SHR could be explained by its direct and specific antiprolifer-
ative effect on vascular smooth muscle cells [30]. Our study
demonstrated that in humans depletion of phenylalanine can
also influence metabolites in its downstream pathway. In
our study, baseline phenylalanine was significantly depleted
in patients with hypertension, and along with its depletion
there was downregulation of many metabolites within the
phenylalanine and tyrosine metabolic pathway (such as
tyrosine and norepinephrine).
Our study illustrates the power of untargeted metabolic
profiling to identify new metabolic pathways implicated in
the development of hypertension. Three metabolic path-
ways were identified including phenylalanine, tyrosine, and
tryptophan biosynthesis, aminoacyl-tRNA biosynthesis, and
nitrogen metabolism pathways, which again emphasizes the
importance of amino acid metabolism in the development
of hypertension.The phenylalanine, tyrosine, and tryptophan
biosynthesis pathwaymay take part in BP regulation through
the antiproliferative effect of phenylalanine on vascular
smooth muscle cells [30]. The nitrogen metabolism pathway
can affect production of nitrogen compounds including
nitric oxide which is evolved in BP regulation. A more
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comprehensive assessment of metabolites involved in these
pathways in a larger sample is warranted and could shed
further light on their mechanisms in BP regulation.
A novel finding of our study was that a higher baseline
lyxose level was associated with a higher risk of hypertension.
Lyxose is an aldopentose, a monosaccharide containing five
carbon atoms including an aldehyde functional group. Lyxose
is a key component of the bacterial cell wall [31] and is
also a fermentation product of gut microbes which was
reported as a potential biomarker of type 2 diabetes mellitus
[32]. Human gut microbes can affect the amount of energy
extracted from the diet and the risk of obesity, which in turn
relates to BP [33]. Moreover, the ARIC study also identified
a product of microbial fermentation, 4-hydroxyhippurate,
which can take part in BP regulation through oxidative
stress [12]. These findings may be associated with metabolic
abnormalities of gut flora and demonstrate the important role
of gut microbes in the development of hypertension. Diet
pattern is known to modulate the composition of the gut
microbiota. Also, products of gut microbial metabolism act
as signaling molecules and influence the host’s metabolism
[34]. Supplementing the diet that stimulates the expansion of
specific microbes to improve metabolic regulation can be a
therapy for metabolic diseases [34]. Recent meta-analysis of
randomized, controlled trials on consumption of probiotics
revealed that probiotics are a potential supplement and
dietary constituent to improve blood pressure and prevent or
control hypertension [35].
This study has several strong points. All individuals were
free of hypertension at the time the blood samples were
collected and this enabled us to investigate the associa-
tion between baseline metabolites and the risk of incident
hypertension. We used a matched case-control design with
extreme phenotype to maximize the efficiency of the study.
We also matched cases and controls for age and gender as
well as baseline systolic BP and adjusted for risk factors at
baseline tominimize potential confounding contributions. In
addition, we applied a pathway approach to highlight the key
associations between metabolic measures and hypertension.
Our study has some potential limitations. First, this is
an exploratory research with small sample size and without
replications study. Therefore the candidate metabolites of
interest from this study should be replicated in studies using
greater sample sizes. Second, to what degree the results
presented here are ethnically specific is unknown. Previ-
ous studies showed there were great metabolic differences
between populations [8]. Whether candidate metabolites
identified from this study have a role in the development of
hypertension in other populations requires further investiga-
tion. In addition, we did not include other factors that might
influence the regulation of blood pressure.
In conclusion, our study identified multiple metabolites
that associated with risk of new onset hypertension. These
findings implied that low amino acid levels and gut micro-
biome might play an important role in the pathogenesis
of hypertension. Further investigation is required to test
whether measurements might help identify metabolic can-
didates for interventions to reduce hypertension risk and to
elucidate the biological mechanisms of BP regulation.
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